Two copper(II) mixed ligand complexes with dicarboxylate bridges were prepared and studied, namely [Cu2(μ-fu)(pmdien)2(H2O)2](ClO4)2 (complex No. 5) and [Cu2(μ-dtdp)(pmdien)2(H2O)2](ClO4)2 (complex No. 6), where H2fu = fumaric acid, pmdien = N,N,N',N″,N″ pentamethyldiethylenetriamine, and H2dtdp = 3,3'-dithiodipropionic acid. The copper atoms are coordinated in the same mode by the tridentate pmdien ligand and oxygen of water molecules, and they only differ in the dicarboxylate bridge. This work is focused on the study of the inhibitory effect of these potential antimicrobial drugs on the activity of the most important human liver drug-metabolizing enzymes, cytochromes P450 (CYP), especially their forms CYP2C8, CYP2C19, and CYP3A4. The obtained results allow us to estimate the probability of potential drug interactions with simultaneously administrated drugs that are metabolized by these CYP enzymes. In conclusion, the presence of adverse effects due to drug-drug interactions with concomitantly used drugs cannot be excluded, and hence, topical application may be recommended as a relatively safe approach.

Department of Inorganic Chemistry Faculty of Science Palacký University Olomouc 17 Listopadu 1192 12 779 00 Olomouc Czech Republic

Department of Pharmacology Faculty of Medicine Palacký University Olomouc Hněvotínská 3 779 00 Olomouc Czech Republic

Laboratory of Growth Regulators Faculty of Science Palacký University and Institute of Experimental Botany of the Czech Academy of Sciences Šlechtitelů 27 78 371 Olomouc Czech Republic

Zobrazit více v PubMed

Stryer L. Biochemistry. 4th ed. W. H. Freeman and Company; New York, NY, USA: 1995.

Solomon E.I., Heppner D.E., Johnston E.M., Ginsbach J.W., Cirera J., Qayyum M., Kieber-Emmons M.T., Kjaergaard C.H., Hadt R.G., Tian L. Copper active sites in biology. Chem. Rev. 2014;7:3659–3853. doi: 10.1021/cr400327t. PubMed DOI PMC

Locatelli M., Farina C. Role of copper in central nervous system physiology and pathology. Neural Regen. Res. 2025;4:1058–1068. doi: 10.4103/NRR.NRR-D-24-00110. PubMed DOI PMC

Molinaro C., Martoriati A., Pelinski L., Cailliau K. Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II. Cancers. 2020;12:2863. doi: 10.3390/cancers12102863. PubMed DOI PMC

Alcock N.W., Tracy V.M., Waddington T.C. Acetates and Acetato-Complexes. Part 2. Spectroscopic Studies. J. Chem. Soc. Dalton Trans. 1976;21:2243–2246. doi: 10.1039/dt9760002243. DOI

Tombers M., Meyer J., Meyer J., Lawicki A., Zamudio-Bayer V., Hirsch K., Lau J.T., von Issendorff B., Terasaki A., Schlathölter T.A., et al. Mn12-Acetate Complexes Studied as Single Molecules. Chem.-Eur. J. 2022;28:e202102592. doi: 10.1002/chem.202102592. PubMed DOI PMC

Mrozinski J. New trends of molecular magnetism. Coord. Chem. Rev. 2005;249:2534–2548. doi: 10.1016/j.ccr.2005.05.013. DOI

Eddaoudi M., Moler D.B., Li H.L., Chen B.L., Reineke T.M., O’Keeffe M., Yaghi O.M. Modular chemistry: Secondary building units as a basis for the design of highly porous and robust metal-organic carboxylate frameworks. Acc. Chem. Res. 2001;34:319–330. doi: 10.1021/ar000034b. PubMed DOI

Ackermann L. Carboxylate-Assisted Ruthenium-Catalyzed Alkyne Annulations by C-H/Het-H Bond Functionalizations. Acc. Chem. Res. 2014;47:281–295. doi: 10.1021/ar3002798. PubMed DOI

Soltani S., Akhbari K., Phuruangrat A. Incorporation of silver nanoparticles on Cu-BTC metal-organic framework under the influence of reaction conditions and investigation of their antibacterial activity. Appl. Organomet. Chem. 2022;36:e6634. doi: 10.1002/aoc.6634. DOI

Soltani S., Akhbari K. Cu-BTC metal-organic framework as a biocompatible nanoporous carrier for chlorhexidine antibacterial agent. J. Biol. Inorg. Chem. 2022;27:81–88. doi: 10.1007/s00775-021-01912-5. PubMed DOI

Yenikaya C., Poyraz M., Sari M., Demirci F., Ilkimen H., Büyükgüngör O. Synthesis, characterization and biological evaluation of a novel Cu(II) complex with the mixed ligands 2,6-pyridinedicarboxylic acid and 2-aminopyridine. Polyhedron. 2009;28:3526–3532. doi: 10.1016/j.poly.2009.05.079. DOI

Yesilel O.Z., Mutlu A., Darcan C., Büyükgüngör O. Syntheses, structural characterization and antimicrobial activities of novel cobalt-pyrazine-2,3-dicarboxylate complexes with N-donor ligands. J. Mol. Struct. 2010;964:39–46. doi: 10.1016/j.molstruc.2009.10.048. DOI

Thornton L., Dixit V., Assad L.O.N., Ribeiro T.P., Queiroz D.D., Kellett A., Casey A., Colleran J., Pereira M.D., Rochford G., et al. Water-soluble and photo-stable silver(I) dicarboxylate complexes containing 1,10-phenanthroline ligands: Antimicrobial and anticancer chemotherapeutic potential, DNA interactions and antioxidant activity. J. Inorg. Biochem. 2016;159:120–132. doi: 10.1016/j.jinorgbio.2016.02.024. PubMed DOI

Alisir S.H., Demir S., Sariboga B., Buyukgungor O. A disparate 3-D silver(I) coordination polymer of pyridine-3,5-dicarboxylate and pyrimidine with strong intermetallic interactions: X-ray crystallography, photoluminescence and antimicrobial activity. J. Coord. Chem. 2015;68:155–168. doi: 10.1080/00958972.2014.978307. DOI

Jaros S.W., da Silva M., Florek M., Smolenski P., Pombeiro A.J.L., Kirillov A.M. Silver(I) 1,3,5-Triaza-7-phosphaadamantane Coordination Polymers Driven by Substituted Glutarate and Malonate Building Blocks: Self-Assembly Synthesis, Structural Features, and Antimicrobial Properties. Inorg. Chem. 2016;55:5886–5894. doi: 10.1021/acs.inorgchem.6b00186. PubMed DOI

Loubalová I., Kopel P. Coordination Compounds of Cu, Zn, and Ni with Dicarboxylic Acids and N Donor Ligands, and Their Biological Activity: A Review. Molecules. 2023;28:1445. doi: 10.3390/molecules28031445. PubMed DOI PMC

Abbaszadeh A., Safari N., Amani V., Notash B., Raei F., Eftekhar F. Mononuclear and Dinuclear Copper(II) Complexes Containing N, O and S Donor Ligands: Synthesis, Characterization, Crystal Structure Determination and Antimicrobial Activity of [Cu(phen)(tda].2H2O) and [(phen)2Cu(µ-tda)Cu(phen)] (ClO4)2.1.5H2O. Iran J. Chem. Chem. Eng.-Int. Engl. Ed. 2014;33:1–13.

Paul A., Figuerola A., Bertolasi V., Manna S.C. DNA/protein binding and magnetic properties of a 1D Cu(II) complex containing fumarate and tridentate Schiff base ligands. Polyhedron. 2016;119:460–470. doi: 10.1016/j.poly.2016.09.028. DOI

Loubalová I., Zahradníková E., Masaryk L., Nemec I., Hochvaldová L., Panácek A., Kvítek L., Vecerová R., Swiatkowski M., Kopel P. Antibacterial study on nickel and copper dicarboxylate complexes. Inorg. Chim. Acta. 2023;545:121273. doi: 10.1016/j.ica.2022.121273. DOI

Anzenbacher P., Anzenbacherová E. Cytochromes P450 and metabolism of xenobiotics. Cell. Mol. Life Sci. 2001;58:737–747. doi: 10.1007/PL00000897. PubMed DOI PMC

Srejber M., Navrátilová V., Paloncyová M., Bazgier V., Berka K., Anzenbacher P., Otyepka M. Membrane-attached mammalian cytochromes P450: An overview of the membrane’s effects on structure, drug binding, and interactions with redox partners. J. Inorg. Biochem. 2018;183:117–136. doi: 10.1016/j.jinorgbio.2018.03.002. PubMed DOI

Mautner F.A., Vicente R., Louka F.R.Y., Massoud S.S. Dinuclear fumarato- and terephthalato-bridged copper(II) complexes: Structural characterization and magnetic properties. Inorg. Chim. Acta. 2008;361:1339–1348. doi: 10.1016/j.ica.2007.08.026. DOI

Pavlishchuk V.V., Kolotilov S.V., Addison A.W., Prushan M.J., Butcher R.J., Thompson L.K. Mono- and trinuclear nickel(II) complexes with sulfur-containing oxime ligands: Uncommon templated coupling of oxime with nitrile. Inorg. Chem. 1999;38:1759–1766. doi: 10.1021/ic981277r. PubMed DOI

Kopel P., Mrozinski J., Dolezal K., Langer V., Boca R., Bienko A., Pochaba A. Ferromagnetic Properties of a Trinuclear Nickel(II) Complex with a Trithiocyanurate Bridge. Eur. J. Inorg. Chem. 2009:5475–5482. doi: 10.1002/ejic.200900617. DOI

Jefcoate C.R. Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy. Methods Enzymol. 1978;52:258–279. doi: 10.1016/s0076-6879(78)52029-6. PubMed DOI

Oesch F., Fabian E., Oesch-Bartlomowicz B., Werner C., Landsiedel R. Drug-metabolizing enzymes in the skin of man, rat, and pig. Drug Metab. Rev. 2007;39:659–698. doi: 10.1080/03602530701690366. PubMed DOI

Špičáková A., Bazgier V., Skálová L., Otyepka M., Anzenbacher P. β-caryophyllene Oxide and Trans-nerolidol Affect Enzyme Activity of CYP3A4-In Vitro and In Silico Studies. Physiol. Res. 2019;68:S51–S58. doi: 10.33549/physiolres.934323. PubMed DOI

Spicakova A., Anzenbacher P., Liskova B., Kuca K., Fusek J., Anzenbacherova E. Evaluation of possible inhibition of human liver drug metabolizing cytochromes P450 by two new acetylcholinesterase oxime-type reactivators. Food Chem. Toxicol. 2016;88:100–104. doi: 10.1016/j.fct.2015.11.024. PubMed DOI

Nguyen L.T., Myslivecková Z., Szotáková B., Spicáková A., Lnenicková K., Ambroz M., Kubícek V., Krasulová K., Anzenbacher P., Skálová L. The inhibitory effects of β-caryophyllene, β-caryophyllene oxide and α-humulene on the activities of the main drug-metabolizing enzymes in rat and human liver in vitro. Chem.-Biol. Interact. 2017;278:123–128. doi: 10.1016/j.cbi.2017.10.021. PubMed DOI

Guengerich F.P. Inhibition of Cytochrome P450 Enzymes by Drugs-Molecular Basis and Practical Applications. Biomol. Ther. 2022;30:1–18. doi: 10.4062/biomolther.2021.102. PubMed DOI PMC

In Vitro Drug Interaction Studies—Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry. FDA, Ed. [(accessed on 20 November 2023)];2020 Available online: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/in-vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions.

Chang T.K., Waxman D.J. Enzymatic analysis of cDNA-expressed human CYP1A1, CYP1A2, and CYP1B1 with 7-ethoxyresorufin as substrate. Methods Mol. Biol. 1998;107:103–109. PubMed

Soucek P. Novel sensitive high-performance liquid chromatographic method for assay of coumarin 7-hydroxylation. J. Chromatogr. B. 1999;734:23–29. doi: 10.1016/S0378-4347(99)00325-4. PubMed DOI

Donato M.T., Jiménez N., Castell J.V., Gómez-Lechón M.J. Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metab. Dispos. 2004;32:699–706. doi: 10.1124/dmd.32.7.699. PubMed DOI

Crespi C.L., Chang T.K., Waxman D.J. High-performance liquid chromatographic analysis of CYP2C8-catalyzed paclitaxel 6 alpha-hydroxylation. Methods Mol. Biol. 1998;107:123–127. PubMed

Crespi C.L., Chang T.K., Waxman D.J. Determination of CYP2C9-catalyzed diclofenac 4′-hydroxylation by high-performance liquid chromatography. Methods Mol. Biol. 1998;107:129–133. PubMed

Mercolini L., Mandrioli R., Iannello C., Matrisciano F., Nicoletti F., Raggi M.A. Simultaneous analysis of diazepam and its metabolites in rat plasma and brain tissue by HPLC-UV and SPE. Talanta. 2009;80:279–285. doi: 10.1016/j.talanta.2009.06.074. PubMed DOI

Crespi C.L., Chang T.K., Waxman D.J. CYP2D6-dependent bufuralol 1′-hydroxylation assayed by reversed-phase ion-pair high-performance liquid chromatography with fluorescence detection. Methods Mol. Biol. 1998;107:141–145. PubMed

Lucas D., Menez J.F., Berthou F. Chlorzoxazone: An in vitro and in vivo substrate probe for liver CYP2E1. Methods Enzymol. 1996;272:115–123. doi: 10.1016/s0076-6879(96)72014-1. PubMed DOI

Guengerich F.P., Martin M.V., Beaune P.H., Kremers P., Wolff T., Waxman D.J. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 1986;261:5051–5060. doi: 10.1016/S0021-9258(19)89213-X. PubMed DOI

Ortiz de Montellano P.R. Cytochrome P450-activated prodrugs. Future Med. Chem. 2013;5:213–228. doi: 10.4155/fmc.12.197. PubMed DOI PMC

Zanger U.M., Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 2013;138:103–141. doi: 10.1016/j.pharmthera.2012.12.007. PubMed DOI

Devi S., Sangeeta. Kumari B. Emugel for topical drug delivery: A novel approach. GSC Biol. Pharm. Sci. 2020;11:104–114. doi: 10.30574/gscbps.2020.11.3.0165. DOI

Schenkman J.B., Jansson I. Spectral analyses of cytochromes P450. Methods Mol. Biol. 1998;107:25–33. PubMed